



Yamaoka-Tojo et al. Cardiovascular Diabetology 2010, 9:17
http://www.cardiab.com/content/9/1/17
Open AccessORIGINAL  INV EST IGATIONOriginal investigationElevated circulating levels of an incretin hormone, 
glucagon-like peptide-1, are associated with 
metabolic components in high-risk patients with 
cardiovascular disease
Minako Yamaoka-Tojo*1, Taiki Tojo2, Naonobu Takahira1, Atsuhiko Matsunaga1, Naoyoshi Aoyama2, Takashi Masuda1 
and Tohru Izumi2
Abstract
Background: Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has a wide range of effects on glucose 
metabolism and cardiovascular function (e.g., improving insulin sensitivity, reduction in appetite, modulation of heart 
rate, blood pressure and myocardial contractility). Metabolic syndrome (MetS) is associated with an increased risk of 
developing atherosclerotic cardiovascular diseases. Novel glycemic control drugs, the dipeptidyl-peptidase-4 (DPP-4) 
inhibitors, work by inhibiting the inactivation of incretin hormones, GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP). In spite of good effects of these drugs in diabetic patients, circulating levels of incretins and their role 
in MetS are largely unknown.
Methods: To examine relationships between incretin hormones and MetS risk factors, we measured circulating levels 
of incretins in obese high-risk patients for cardiovascular disease. Fasting serum GLP-1 and GIP levels were measured by 
ELISA. We performed a cross-sectional analysis of metabolic variables in the fasting state in two subject groups: with 
MetS (n = 60) and pre-MetS (n = 37).
Results: Fasting levels of Serum GLP -1 in the peripheral circulation were significantly increased correlated with the 
accumulation of MetS risk factors components (r = 0. 470, P < 0.001). There was a significant interaction between 
circulating GLP-1 and GIP, serum high-density lipoprotein cholesterol, triglyceride, and serum uric acid concentrations 
but not waist circumference, fasting glucose, HbA1c, or presence of diabetes.
Conclusion: Circulating levels of GLP-1 in relation to the accumulation in MetS factors suggested that MetS patients 
with elevated levels of GLP-1 are high-risk patients for cardiovascular disease, independent with the presence of 
diabetes.
Background
The metabolic syndrome (MetS) is a major public health
problem [1] and a multiple risk factor for cardiovascular
disease [2,3]. It consists of atherogenic dyslipidemia (ele-
vated triglycerides and low high-density lipoprotein
[HDL]), and elevations of blood pressure and glucose,
and abdominal obesity with pro-thrombotic and proin-
flammatory states [1]. MetS is associated with a 5-fold
higher risk of developing type 2 diabetes and 2.6-to 3-fold
high risk of cardiovascular disease [4,5]. The pathophysi-
ology of MetS is not well defined, and several investiga-
tors have sought to identify a unifying factor that could
explain all the components of the syndrome. In addition
to insulin resistance/hyperinsulinemia, investigators have
found several biomarkers to be associated with MetS
including leptin [4], catecholamine [6], brain natriuretic
peptide (BNP) [7], oxidized low-density lipoprotein cho-
lesterol (LDL)[8], uric acid [9], C-reactive protein (CRP)
[4], plasminogen activator inhibitor-1 [4], aldosterone [4],
cyctatin C [10], and carboxy-terminal prevasopress in
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perturbations in MetS [11].
Glucagon-like peptide-1 (GLP-1) is a hormone derived
from the prepro-glucagon molecule and is secreted by
intestinal L cells [12]. It is the most potent stimulator of
glucose-induced insulin secretion and also suppresses in
vivo acid secretion by gastric glands. Intracerebroventric-
ular GLP-1 is powerfully inhibited in fasting rats [13]. In
addition, injection of a specific antagonist of GLP-1
blocked the inhibitory effect of GLP-1 on food intake.
GLP-1 receptor is expressed in the central nervous sys-
tem or in the stomach except β cells of the pancreas, and
its every function such as inhibition of insulin secretion,
appetite suppression and gastric motor inhibition has a
hypoglycemic effect. Thus, the development of GLP-1-
releated study as a diabetic drug (e.g., GLP-1 analogs and
the dipeptidyl-peptidase-4 [DPP-4] inhibitors) is pro-
gressing.
We therefore hypothesized that circulating GLP-1
would be associated with insulin resistance/hyperinsu-
linemia and MetS. To examine relationships between
incretin hormones and MetS components, we measured
circulating levels of incretins, GLP-1 and gastric inhibi-




The study included 97 Japanese high-risk outpatients for
cardiovascular disease with abdominal obesity (40%
female) in the Obesity/Metabolic Syndrome Clinic,
Department of Cardioangiology, Kitasato University Hos-
pital. The only exclusionary criterion at enrolment was
the treatment with antidiabetic drugs including insulin
and oral agents. All subjects gave informed consent
before participating in this study, and the ethics commit-
tee of the Kitasato University Hospital approved the study
design. Body mass index (BMI) was calculated as weight
divided by height squared. Systolic and diastolic blood
pressure was measured after a rest for at least 15 minutes
with a sphygmomanometer in sitting position. Homeo-
stasis model assessment (HOMA-IR) was used as a mea-
sure of insulin resistance and was calculated as fasting
plasma insulin (μU/mL) × glucose (mg/dL)/405 [14].
Metabolic scores were calculated using MetS compo-
nents according to the Japanese MetS criteria [15]. The
score consisted of four independent components as
abdominal obesity, defined as a waist circumference ≥85
cm in men or ≥90 cm in women, hypertriglyceridemia
and/or low HDL-cholesterolemia, hypertension, and ele-
vated fasting glucose. The diagnosis of hypertension was
established based on blood pressure levels measured at
the study visit (≥130/85 mmHg) or a prior diagnosis of
hypertension and current treatment with antihyperten-
sive medications. Diabetes/impaired fasting glucose
(IFG) was considered present if the subject had history of
diabetes or had a fasting glucose level of 110 mg/dL or
greater.
Measurement of clinical biomarkers
Blood samples were collected by venipuncture after an
overnight fast. Serum was centrifuged (1500 g for 15 min
at 4°C) and stored at 4°C until measurement within cou-
ple days for biochemical markers, such as triglyceride,
LDL cholesterol, HDL cholesterol, insulin, plasma glu-
cose, glycated haemoglobin (HbA1c), uric acid, CRP, and
BNP were measured enzymatically in the clinical labora-
tory of Kitasato University Hospital.
Measurement of incretin hormones
Circulating levels of human GLP-1 and GIP were deter-
mined by enzyme-linked immunosorbent assay (ELISA)
using the GLP-1 (7-36) amide/prepro-glucagon (98-127)
amide enzyme immuno assay EIA kit (Phoenix Pharma-
ceuticals, Inc., Burlingame, CA) and the human GIP assay
kit (Immuno-Biological Laboratories Co., Ltd., Takasaki,
Japan), respectively.
Statistical analysis
Continuous data were summarized as either mean ± SD
or median and quartiles, and categorical data were
expressed as percentages. Data were compared by
unpaired t-test or Mann-Whitney U-tests where appro-
priate. Differences in proportions of variables were deter-
mined by chi-squared analysis. To evaluate the
correlations between GLP-1 and selected variables, we
calculated Spearman correlation coefficients between cir-
culating levels of fasting GLP-1 and the following vari-
ables: 1)conventional risk factors for cardiovascular
disease (LDL cholesterol, HDL cholesterol, triglyceride,
HbA1c, presence of hypertension, and current smoking),
and history of coronary artery disease; 2) measures of
adiposity and insulin resistance (BMI, waist circumfer-
ence, fasting blood glucose, insulin level, and HOMA-IR);
and 3) metabolic risk scores (abdominal obesity, hyper-
tension, high triglyceride and/or low HDL cholesterol,
and glucose intolerance or diabetes) and MetS-related
co-morbidity (hyper uric academia, fatty liver disease,
chronic kidney disease, and sleep apnea syndrome). Par-
ticipants having low metabolic scores (0, 1, or 2) was
termed the pre-MetS whereas patients having high meta-
bolic scores (3 or 4) were defined as MetS.
To evaluate the association of GLP-1 with MetS, we
constructed multivariable logistic regression models to
assess whether circulating GLP-1 was independently
associated with MetS. We calculated the odds ratio for
the presence of MetS in quartiles of GLP-1 with partici-
pants in the lowest quartile of GLP-1 considered the ref-
erent group. Adjustments were performed for age and
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ues < 0.05 were considered significant.
Results
Clinical characteristics and metabolic variables
Sixty patients of MetS and 37 patients of pre-MetS with
atherosclerosis-prone conditions participated in the
study. The patients with MetS were older than pre-MetS
patients but the proportion of women was not different
between the groups (Table 1). In MetS patients, BMI was
greater than in pre-MetS patients (average BMI 32.1 vs.
29.0, P = 0.015). Thirty-seven of patients (62%) with MetS
were hypertension and used one or more antihyperten-
sive drugs. A half of the patients with MetS were treated
with calcium-channel blockers. Twelve patients with
MetS and three patients with pre-MetS were diagnosed
IFG or type 2 diabetes. None of patients received antidia-
betic drugs including insulin. Fasting plasma glucose lev-
els were higher in patients with pre-MetS than with MetS
(P = 0.025). Predictably, HDL cholesterol was lower in the
patients with MetS compared with pre-MetS (P = 0.001).
Thirty-eight of the patients with MetS were diagnosed
dyslipidemia and 45% of the patients received statins
whereas only 19% of the patients with pre-MetS used sta-
tins (P = 0.016). The proportion of participants who have
previous and/or current coronary artery disease was sig-
Table 1: Participant characteristics (n = 97).
MetS (n = 60) Pre-MetS (n = 37) P-value
Age (year) 52.8 ± 14.2 50.3 ± 16.6 0.494
Sex, female (%) 22 (36.7%) 17 (45.9%) 0.333
BMI (kg/m2) 32.1 ± 6.5 29.0 ± 4.9 0.015
Waist circumference (cm) 103 ± 15 98 ± 11 0.093
Plasma glucose (mg/dL) 114 ± 28 130 ± 41 0.025
Plasma insulin (IU/mL) 33.0 ± 36.4 33.4 ± 37.5 0.961
HOMA-IR 4.8 ± 6.6 4.7 ± 7.0 0.944
LDL cholesterol (mg/dL) 129 ± 33 121 ± 36 0.366
HDL cholesterol (mg/dL) 50.5 ± 11.9 61.1 ± 12.4 0.001
Triglyceride (mg/dL) 235 ± 224 151 ± 128 0.200
HbA1c (%) 5.7 ± 0.9 5.8 ± 1.0 0.605
CRP (μg/dL) 254 ± 575 156 ± 226 0.323
Smoking, n (%) 14 (23.3%) 11 (29.7%) 0.484
Hypertension, n (%) 37 (61.7%) 20 (54.1%) 0.623
Diabetes/IFG, n (%) 21 (35.0%) 14 (37.8%) 0.658
Dyslipidemia, n (%) 38 (63.3%) 18 (48.6%) 0.236
Coronary artery disease, n (%) 13 (21.7%) 2 (5.4%) 0.027
Hyper uric acidemia 14 (23.3%) 10 (27.0%) 0.596
Fatty liver disease 10 (16.7%) 11 (29.7%) 0.102
Chronic kidney disease 5 (8.3%) 2 (5.4%) 0.627
OSAS, n (%) 4 (6.7%) 1 (2.7%) 0.416
Statin use, n (%) 27 (45.0%) 7 (18.9%) 0.016
Diuretic use, n (%) 12 (20.0%) 6 (16.2%) 0.658
β-blockers, n (%) 21 (35.0%) 13 (35.1%) 0.899
RAAS inhibitors, n (%) 10 (16.7%) 6 (16.2%) 0.985
Ca-channel blockers, n (%) 31 (51.7%) 14 (37.8%) 0.326
Aspirin, n (%) 21 (35.0%) 7 (18.9%) 0.117
Metabolic score (0, 1, 2, 3, and 4) 3.3 ± 0.5 1.5 ± 0.7 <0.001
Continuous variables are presented as mean ± SD whereas categorical variables are presented as counts and percentages. BMI, body mass 
index; HOMA-IR, homeostatis model assessment; LDL, low density lipoprotein; HDL, high density lipoprotein; HbA1c, glycated haemoglobin; 
IFG, impaired fasting glucose; OSAS, obstructive sleep apnea syndrome; RAAS, rennin-angiotensin-aldosterone system; Ca-channel, calcium 
channel.
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MetS (P = 0.027). However, circulating levels of BNP, a
useful biomarker for heart failure, did not differ between
the 2 groups.
Circulating levels of GLP-1 are increased in MetS
As shown in Figure 1, the serum GLP-1 concentration
was on average 28% higher in MetS patients (7.7 ± 1.9 ng/
mL)compared to pre-MetS subjects (6.0 ± 1.6 ng/mL, P <
0.001). This difference remained significant after control-
ling for age and sex (P = 0.010). When the data from the
patients with MetS and pre-MetS were combined, GLP-1
levels were similar in men (7.0 ± 2.0 ng/mL) and women
(7.2 ± 2.0 ng/mL) (P = 0.709). We next compared patient
groups on the basis of the number of MetS criteria that
were concomitantly present (Figure 2). Serum GLP-1 lev-
els elevated with increasing number of MetS components
(P < 0.001; Figure 2A). Among MetS components, the
presence of dyslipidemia (high triglyceride and/or low
HDL cholesterol) was significantly related to circulating
levels of GLP-1. On the other hand, there was no correla-
tion between the accumulation of MetS components and
serum levels of GIP (Figure 2B).
Association of serum GLP-1 and GIP with clinical variables
Circulating GLP-1 positively correlated with fasting
serum triglycerides, uric acid, and CRP, and inversely cor-
related with HDL cholesterol (Table 2). Above all, serum
GLP-1 was powerfully associated with a useful biomarker
for systemic inflammation, serum CRP(r = 0.550, P =
0.026). In addition, circulating levels of GIP were signifi-
cantly associated with GLP-1 (r = 0.383, P < 0.001). Inter-
estingly, serum GIP was positively correlated with serum
levels of LDL cholesterol and hyper uric acidemia with or
without medications. However, no significant correlation
was observed between serum GIP and the stating or
allopurinol usage. In addition, there was no correlation
between serum GIP and MetS scores. Although each
variable has a large dispersion, the serum GIP concentra-
tion was on average three times higher in MetS patients
(19.0 ± 45.7 pg/mL) compared to pre-MetS subjects (6.5
± 10.2 pg/mL) (P = 0.034).
Association of serum GLP-1 with the presence of MetS
In multivariable logistic regression analyses that adjusted
for age and sex, circulating GLP-1 levels in the forth
quartile were significantly associated with higher odds
ratios (OR) of having MetS (Table 3). This association
remained significant after additional adjustment for sta-
tin use, history of coronary artery disease, and diuretic
Figure 1 Circulating levels of glucagon-like peptide-1 (GLP-1) in 
patients with metabolic syndrome (MetS) and pre-MetS condi-
tions. Scatter plot showing the GLP-1 (ng/mL) in patients with pre-































Figure 2 Association between serum levels of incretins, gluca-
gon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide 
(GIP), and metabolic syndrome components in patients with ath-
erosclerosis-prone conditions. Circulating levels of GLP-1 (A) and GIP 
(B) were measured in high-risk patients with atherosclerosis. Metabolic 
score is the number of metabolic syndrome components; abdominal 
obesity, hypertension, dyslipidemia (high triglyceride and/or low high 
density lipoprotein cholesterol), and hyperglicemia (impaired glucose 
tolerance or diabetes). Progressive increase in GLP-1 level as a function 
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quartile.
Discussion
The present study, to the best of our knowledge, is the
first to report that circulating fasting levels of GLP-1 is
associated with the accumulation in MetS components.
Participants with MetS had higher mean GLP-1 levels
than those without MetS and participants in the fourth
quartiles for serum GLP-1 had markedly higher odds of
MetS compared with those in the bottom quartile (Table
3). In addition, serum GLP-1 levels were increased in par-
ticipants who had greater clustering of MetS components
(Figure 2A). These associations were independent of adi-
posity or the presence of diabetes/IFG. Furthermore,
serum GLP-1 was positively correlated with serum CRP.
These data suggested that MetS patients with elevated
levels of GLP -1 are high-risk patients for cardiovascular
disease, independent with the presence of diabetes. Gas-
trointestinal hormones (such as GLP-1 or GIP) that come
under incretin, are secreted by intestine in response to
nutrient ingestion [16]. Originally, it has been thought
that they are gastrointestinal factors involved in post-
ingestion augmented secretion of insulin by β cell of the
pancreas [17]. According to previous literature, GLP-1
and GIP are both secreted within minutes ingestion and
facilitate the rapid disposal of ingested nutrients [18].
GLP-1 promotes satiety and sustained GLP-1 receptor
activation is associated with weight loss in both preclini-
cal and clinical studies [19]. As shown in Figure 2A, circu-
lating levels of GLP-1 were correlated with MetS score in
patients with MetS. On the other hand, there was no sig-
Table 2: Spearman correlations between GLP-1, GIP, and selected variables in patients with MetS and pre-MetS conditions 
(n = 97).
GLP-1 r P-value GIP r P-value
Age (years) 0.004 0.145 0.009 0.938
Sex 0.202 0.046 -0.063 0.603
Waist 0.078 0.464 0.274 0.310
BMI 0.089 0.747 0.486 0.056
LDL cholesterol (mg/dL) 0.204 0.093 0.357 0.003
HDL cholesterol (mg/dL) -0.229 0.049 -0.009 0.941
Triglyceride (mg/dL) 0.243 0.023 0.041 0.730
Smoking 0.118 0.326 -0.133 0.274
CRP (μg/dL) 0.550 0.026 -0.047 0.694
Plasma glucose (mg/dL) 0.064 0.554 -0.388 0.140
Plasma insulin (IU/mL) 0.069 0.571 0.088 0.499
HOMA-IR -0.116 0.284 0.013 0.920
Diabetes/IFG 0.049 0.652 -0.132 0.278
HbA1c -0.303 0.212 -0.029 0.810
Hypertension 0.059 0.589 0.197 0.099
Dyslipidemia 0.031 0.773 0.011 0.925
Coronary artery disease 0.093 0.391 -0.094 0.439
Hyper uric acidemia 0.133 0.219 0.276 0.019
Serum uric acid (mg/dL) 0.245 0.025 -0.023 0.849
Fatty liver disease -0.054 0.618 -0.115 0.340
Chronic kidney disease 0.029 0.793 -0.046 0.703
OSAS 0.178 0.099 -0.014 0.908
Metabolic score 0.470 <0.001 0.157 0.189
GIP (pg/mL) 0.383 <0.001
GLP-1, glucagon-like peptide-1; GIP, gastric inhibitory polypeptide; r, Spearman correlation coefficients; BMI, body mass index; LDL, low 
density lipoprotein; HDL, high density lipoprotein; CRP, C-reactive protein; HOMA-IR, homeostatis model assessment; IFG, impaired fasting 
glucose; HbA1c, glycated haemoglobin; OSAS, obstructive sleep apnea syndrome.
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MetS score (Table 2). According to a previous report, cir-
culating GIP was not elevated in diabetic patients [20].
One of the reasons why there was no correlation between
circulating GIP and MetS component may be due to large
dispersion of circulating GIP levels in these patients.
Unfortunately, we don't have enough data to determine a
role on elevated levels of circulating GIP in patients with
MetS. In a previous report about GLP-1 or GIP infusion
to human, GLP-1 is a physical incretin and more power-
ful than GIP [16]. Therefore, we focused on circulating
levels of GLP-1 in the present study. Earlier reports
showed that GIP receptor is expressed in cells, such as β
cells of the pancreas, adipocytes, or osteoblastic cells, and
it plays essential roles in reserving inghested nutrients
within the body in each cell. It has been reported that the
control of the GIP signal can lead to improvement of
MetS [21-24]. According to a previous study using mice
with an inactivated GIP receptor, the duodenal hormone
GIP directly links over-nutrition to obesity [22]. In a pre-
vious animal model, double incretin receptor knockout
mice (Glp1r-/- and Gipr-/-) fed a high-fat diet exhibited
increased energy expenditure [24]. In recent studies,
GLP-1 receptors are expressed in the pancreas, brain,
heart, vasculature, lung, kidney, and gastrointestinal tract
[17]. These data suggest that circulating levels of GLP -1
may affect to systemic metabolism in multiple organs
including cardiovascular systems as a multifunctional
hormone.
Recent studies have demonstrated that GLP-1 receptor
agonists have wide-ranging cardiovascular actions, such
as modulation of heart rate, blood pressure, vascular
tone, and myocardial contractility [25]. Importantly, is
appears that these agents may also have beneficial effects
in the setting of cardiovascular disease. For example, GLP
-1 has been found to exert cardioprotective actions in
experimental models of dilated cardiomyopathy, hyper-
tensive heart failure, and myocardial infarction. More-
over, preliminary clinical studies also indicate that GLP-1
infusion may improve cardiac contractile function in
chronic heart failure patients with and without diabetes,
and in myocardial infarction patients after successful
angioplasty [26,27]. The precise mechanisms underlying
the beneficial effects of GLP -1 in cardiac ischemia have
yet to be established [25]. However, several experimental
studies indicate that they occur independently of effects
on glucose metabolism and may involve activation of
cyclic guanosine monophosphate/cyclic adenosine
monophosphate-dependent pathways and prosurvival
kinases such as PI3K, Akt, glycogen synthase kinase-3β,
p70s6 kinase, ERK1/2, and p38 MAPK [28-33].
Although further basic mechanistic research together
with clinical investigations and metaanalyses are
required, GLP-1-related drug compounds could exert
beneficial effects on not only diabetes but also the cardio-
vascular system in patients with MetS. Several studies
have shown that the magnitude of nutrient-stimulated
insulin secretion is diminished in subjects with type 2
diabetes, promoting investigation as to whether incretin
secretion and/or incretin action is diminished in diabetic
subjects [34]. Plasma levels of GIP appear normal to
increased in subjects with type 2 diabetes, whereas meal-
stimulated plasma levels of GLP-1 are modestly but sig-
nificantly diminished in patients with impaired glucose
tolerance and in subjects with type 2 diabetes [20,35].
Based on the results of this clinical study, significant dif-
ferences were found in fasting serum levels of GLP-1
between the MetS group and the pre-MetS group. On the
other hand, no significant differences in GLP-1 concen-
tration between the diabetes/IFG group and the control
(normal fasting glucose) group (data not shown). The
reason of the difference may come from the diabetes/IFG
group including only early stage diabetes patients
untreated with antidiabetic agents but not moderate to
severe diabetes patients treated with oral antidiabetic
agents and/or insulin.
Table 3: Association of serum GLP-1 with the presence of MetS: logistic regression analyses.
OR (95% CI)
P value
First quartile Second quartile Third quartile Fourth quartile
GLP-1 (ng/mL) <5.7 5.7-7.2 7.2-8.2 >8.2
Unadjusted 1 0.68 (0.14-3.35) 0.643 3.67 (0.87-15.4) 0.076 5.16 (1.23-21.56) 0.025
Age adjusted 1 0.746 (0.15-3.86) 0.746 3.75 (0.89-15.9) 0.072 5.56 (1.30-23.9) 0.021
Fully adjusted 1 0.777 (0.13-4.56) 0.780 3.57 (0.72-17.7) 0.119 8.036 (1.50-42.9) 0.015
The fully adjusted model includes age, sex and body mass index. OR, odds ratios; CI, confidence interval; GLP-1, glucagon-like peptide-1.
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MetS is largely unknown, secretion of GLP-1 mostly
depends upon the specific nutrient composition of the
meal, and it has been reported that a particular caloric
threshold or nutrient delivery rate must be reached in
order to trigger significant secretion [36]. Generally,
MetS patients tend to have a binge -eating disorder and it
may be one of the causes of elevated levels of GLP-1 in
patients with MetS. Even though the results of the study
revealed no significant differences in fasting insulin and
HOMA -IR between the MetS group and the pre-MetS,
the levels of fasting glucose were significantly increased
in the MetS group. Thus, these results suggest that the
accumulation of MetS components induces the elevation
of serum GLP-1 accompanied by increased levels of CRP
(Table 1). Based on these observations, it is thus possible
that high levels of GLP-1 may exhibit predictive informa-
tion for atherosclerosis in patients with MetS.
In the present study, we found serum GLP-1 to be inde-
pendently associated with several components of MetS
including adiposity (BMI) and dyslipidemia (lower HDL
cholesterol and/or high triglyceride levels) (Table 2). In
our speculation, the association of GLP-1 with higher
triglyceride levels may be secondary to increased hepatic
synthesis of triglycerides under influence of glucocorti-
coids, glucagon, and obesity and/or MetS -induced sym-
pathetic nervous system activation [11].
Interestingly, fasting levels of GLP-1 were significantly
lower in patients after gastric bypass surgery compared
with morbidly overweight controls [37,38]. Gastric
bypass causes rapid resolution of insulin resistance and
improved insulin secretion, perhaps mediated in part by
increased GLP-1 [39], even before major weight loss has
been achieved [40]. Although our study cannot demon-
strate causation, it is important to note that fasting levels
of GLP-1 might be linked to improve insulin resistance in
obese patients. In this respect, circulating GLP-1 may be
a novel biomarker for improving insulin sensitivity in
high -risk patients for cardiovascular disease.
Concerning the glucose metabolism, excess glucagon
secretion, abnormally accelerated gastric emptying dur-
ing hyperglycemia, obesity, and increased food intake all
contribute to hyperglycemia [41]. The progressive
impairment of β cell function and increased insulin
demand as tissue becomes insulin resistance are core
pathophysiologic defects in the development of hypergly-
cemia in type 2 diabetes [42,43]. One of the major mecha-
nisms of the genesis and progression of type 2 diabetes is
progressive ectopic lipid deposition (e.g., in myocytes and
hepatocytes, rather than in adipocytes), which induces
insulin resistance, cell lipotoxicity, and diminished cell
function, leading to metabolically inadequate insulin
secretion [44]. Impaired release or action of GLP-1
increases excessive insulin secretion, and may play a role
in the development and/or progression of type 2 diabetes
in patients with MetS [45,46]. Furthermore, postprandial
GLP-1 response is positively associated with changes in
neuronal activity of brain areas implicated in satiety and
food intake regulation in humans [47]. In a previous
report, circulating levels of GLP-1 were decreased in
patients with type2 diabetes [31].
In a recent study, a GLP-1 analog was effective on obese
patients compared to a previous anti-obese drug, olristat.
From these data, we speculate that elevating levels of
GLP-1 in patients with MetS suggest the presence of sys-
temic hyper GLP -1 concentration-induced "GLP-1 resis-
tance" or "GLP-1 dysfunction" in those patients like as
insulin resistance or leptin resistance (Figure 3). This new
concept may shed further light upon the mechanisms
involved in the GLP-1-inducing effect on the systemic
metabolic disorder. In this point, treatment with GLP-1
mimetic agents, including DPP-4 inhibitors and GLP-1
analogs, may be a novel therapeutic strategy for patients
with not only diabetes but also MetS and atherosclerosis-
prone conditions.
Conclusions
In summary, higher circulating levels of GLP-1 are associ-
ated with accumulations of MetS scores and systemic
inflammation, independent of the presence of diabetes.
Circulating GLP-1 may be a novel biomarker for high-risk
patients with MetS, and further studies are warranted to
assess its utility as a predictor of incident MetS and
atherogenic conditions. Our findings may suggest a novel
pathophysiological mechanism underlying over nutrition,
elevated levels of circulating GLP-1, and metabolic syn-
drome.
Figure 3 Mechanism by which excessive circulating levels of GLP-
1 may lead to insulin resistance and metabolic syndrome. GLP-1, 
glucagon-like peptide-1.
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